Last reviewed · How we verify
Ubiquinol
Ubiquinol is a Small molecule drug developed by Beth Israel Deaconess Medical Center. It is currently in Phase 3 development. Also known as: coenzyme Q10, Coenzyme Q10, CoQ10, CoQ10.
Ubiquinol is a reduced form of coenzyme Q10, specifically ubiquinol-10, which is commonly found in humans. It has been studied in clinical trials for various conditions, including diabetes, burn injury, chronic fatigue syndrome, oxidative stress, and inflammation, using water-soluble ubiquinol as an intervention.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ubiquinol |
|---|---|
| Also known as | coenzyme Q10, Coenzyme Q10, CoQ10, CoQ10 |
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- MSA-01 in Multiple System Atrophy (PHASE3)
- Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations (PHASE2, PHASE3)
- Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women (NA)
- Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients (PHASE2)
- Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans (PHASE2)
- Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder (PHASE2)
- Ubiquinone vs. Ubiquinol Supplementation (PHASE2)
- MitoQ and Exercise Effects on Vascular Health (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ubiquinol CI brief — competitive landscape report
- Ubiquinol updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI
Frequently asked questions about Ubiquinol
What is Ubiquinol?
Who makes Ubiquinol?
Is Ubiquinol also known as anything else?
What development phase is Ubiquinol in?
Related
- Manufacturer: Beth Israel Deaconess Medical Center — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: coenzyme Q10, Coenzyme Q10, CoQ10, CoQ10
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing